Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to the discovery of new drug targets and the development of new therapeutic products, today announced the conclusion of a global collaboration with I-Mab, a company global bio-pharmaceutical listed on Nasdaq, to ​​develop and market multiple bispecific antibodies (BsAb) based on the monoclonal antibody developed by Genechem and the antibodies selected by I-MAB. "This collaboration is the first in a long series that will take advantage of Genechem's Good Research Practices (GRP) and CHAMP antibody discovery platform, its robust bioinformatics database, as well as the expertise in developing synergistic partners, in order to provide globally competitive assets based on innovative targets. We are excited to collaborate with I-Mab, a global leader in oncology and antibody development, to bring more products to meet the unmet clinical needs of patients in China and in the world, ”commented Yueqiong Cao, founder and CEO of Genechem.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!